Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 22, 2026 06:00 ET | Source: Greenwich LifeSciences, Inc.

Greenwich LifeSciences Announces FDA Approves Use of Commercially Manufactured GP2 in FLAMINGO-01

STAFFORD, Texas, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,...
January 21, 2026 04:56 ET | Source: Research and Markets

Breast Cancer Imaging Market Size, Share & Trends Analysis Report 2025-2033 by Stage of Care (Diagnostic, Monitoring), End Use (Hospitals, Breast Care Centers), Technology and Region

Dublin, Jan. 21, 2026 (GLOBE NEWSWIRE) -- The "Breast Cancer Imaging Market Size, Share & Trends Analysis Report by Stage of Care (Diagnostic, Monitoring), End Use (Hospitals, Breast Care...
January 12, 2026 07:05 ET | Source: Boehringer Ingelheim Limited

Boehringer Ingelheim announces clinical collaboration with Jazz Pharmaceuticals to advance HER2-targeted therapy in breast cancer

Boehringer and Jazz Pharma partner to combine two unique HER2-targeted approaches, aiming to offer new breast cancer treatment options.
January 09, 2026 07:00 ET | Source: Athira Pharma, Inc.

Athira Pharma Announces Name Change to LeonaBio, Inc. with New Ticker “LONA”

Athira Pharma, Inc. today announced that it has changed its name to LeonaBio, Inc.
January 08, 2026 11:00 ET | Source: ALX Oncology

ALX Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology"; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel...
January 08, 2026 08:30 ET | Source: ALX Oncology

ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004

- First patient dosed in Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and physician’s choice of chemotherapy in HER2-positive metastatic breast cancer; interim...
January 08, 2026 02:00 ET | Source: Tensive

Tensive reports positive pivotal trial top-line results showing REGENERA™ bioresorbable device may transform breast reconstruction

Clinical data from pivotal trial in patients undergoing lumpectomy confirm strong safety profile and growing performance benefits Primary safety endpoint met and encouraging secondary performance...
December 18, 2025 07:02 ET | Source: Athira Pharma, Inc.

Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million

Phase 3 Development Program of Novel Selective Estrogen Receptor Modulator (SERM) Represents Potential Multi-Billion Dollar Opportunity as Treatment Option for Patients with ESR1-Mutations Financing...
December 17, 2025 09:00 ET | Source: Incyclix Bio

Incyclix Bio Expands Board of Directors with Appointment of Dr. Kimberly Blackwell

RESEARCH TRIANGLE PARK, N.C., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Incyclix Bio, LLC, a next-generation cell cycle control company developing INX-315, a novel, potent and selective CDK2 inhibitor for...
December 11, 2025 11:05 ET | Source: Io Therapeutics, Inc.

Io Therapeutics, Inc., presents today at the San Antonio Breast Cancer Symposium preclinical studies demonstrating effectiveness of IRX4204, the company’s clinical stage retinoid X nuclear receptor (RXR) agonist compound, for synergistically promoting killing of HER2+ breast cancer cells in combination with HER2-targeted chimeric antigen receptor modified T-cells (CAR-T).

Io Therapeutics announced today data demonstrating effectiveness of its RXR agonist IRX4204 for synergistic killing of HER2+ breast cancer with CAR-T cells